Julia Kelley
Nurse Practitioner · Puyallup, WANPI 1578896338
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.8% of the total across 298 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 36 manufacturers, the largest accounting for just 13.9% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $2,323, 4.2 times the $552 reported in 2021. Among nurse practitioner clinicians in WA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 298 payments — averaging $21.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$890
- Corcept Therapeutics$570
- Abbott$472
- Sanofi-aventis U.S. LLC$458
- Boehringer Ingelheim$435
- Lilly USA, LLC$420
- plus $3K from 30 others
What the payments were for
- Food & beverage$6,31299%
- Education$190%
- Gifts$591%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 41 | $890 |
| Corcept Therapeutics | 25 | $570 |
| Abbott | 24 | $472 |
| Sanofi-aventis U.S. LLC | 21 | $458 |
| Boehringer Ingelheim | 18 | $435 |
| Lilly USA, LLC | 19 | $420 |
| Amgen | 19 | $385 |
| Dexcom, Inc. | 12 | $287 |
| Antares Pharma, Inc. | 9 | $270 |
| AstraZeneca(2 entities) | 13 | $267 |
| AbbVie | 11 | $224 |
| Tandem Diabetes Care, Inc. | 7 | $217 |
| Bayer | 10 | $208 |
| Mannkind Corporation | 15 | $200 |
| IBSA Pharma Inc. | 10 | $198 |
| Xeris Pharmaceuticals, Inc. | 6 | $126 |
| Madrigal Pharmaceuticals | 3 | $87 |
| Insulet Corporation | 4 | $83 |
| Medtronic | 3 | $78 |
| Radius Health, Inc. | 4 | $78 |
| Novartis | 3 | $68 |
| Ultragenyx Pharmaceutical Inc. | 3 | $53 |
| Ascensia Diabetes Care US Inc. | 2 | $35 |
| Kyowa Kirin, Inc. | 2 | $34 |
| Nevro Corp. | 1 | $32 |
| Recordati_rare_diseases_inc. | 2 | $28 |
| BETA Bionics, Inc. | 2 | $27 |
| Sequel Med Tech, LLC | 1 | $23 |
| Zealand Pharma US, Inc. | 1 | $22 |
| Amryt Pharma Holdings Ltd | 1 | $21 |
| Acella Pharmaceuticals, LLC | 1 | $21 |
| Amphastar Pharmaceuticals, Inc. | 1 | $19 |
| Lifescan, Inc. | 1 | $18 |
| Cequr Corporation | 1 | $15 |
| EUSA Pharma (US) LLC | 1 | $12 |
| Roche Diabetes Care, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,390 in reported general payments places this provider in the 95th percentile of 2,466 nurse practitioner providers in Washington.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 63 | $103,001 |
| OzempicSemaglutide | 70 | $85,878 |
| JardianceEmpagliflozin | 63 | $57,757 |
| TrulicityDulaglutide | 26 | $50,976 |
| Humalog Kwikpen U-200Insulin Lispro | 16 | $42,262 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 28 | $38,865 |
| Tresiba Flextouch U-200Insulin Degludec | 25 | $28,186 |
| RybelsusSemaglutide | 21 | $25,817 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 17 | $25,103 |
| Novolog FlexpenInsulin Aspart | 58 | $19,774 |
| JanuviaSitagliptin Phosphate | 24 | $19,561 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 27 | $19,206 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 14 | $19,040 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 101 | $17,235 |
| Tresiba Flextouch U-100Insulin Degludec | 20 | $16,903 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity, Humalog | $420 | $160,612104 claims |
| Novo NordiskOzempic, Rybelsus, Novolog | $890 | $120,305115 claims |
| Boehringer IngelheimJardiance | $435 | $57,75763 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $458 | $38,86528 claims |
| AstraZenecaFarxiga | $267 | $15,34612 claims |
| AbbVieSynthroid | $224 | $1,78623 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,466 nurse practitioner providers in Washington.
Other nurse practitioner in Puyallup
- Heather HokansonPuyallup$5K
- Olga VoloshinaSeattle$279K
- Sandra ChristensenSeattle$244K
- Felicia ForrestLynnwood$206K
- Amaris MurphyBellevue$146K
- Sonia GlennieSeattle$78K
- Megan WildesTacoma$72K
- Kate KennedyBellevue$63K
- Vicki HainesPasco$57K
- Jessica ArmitageSumner$46K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.